Park, Eun Young Jang, Mihue Kim, Jong Hwan Ahn, Hyung Jun 2024-01-20T08:32:17Z 2024-01-20T08:32:17Z 2022-01-10 2014-11 1742-7061 https://pubs.kist.re.kr/handle/201004/126155 In nature, there exist a wide range of dsRNA-binding proteins that have different binding modes for small interfering RNA (siRNA) as well as structural differences, and some of these proteins have potential as effective siRNA delivery carriers. In order to deliver siRNA into cancer cells, a dsRNA-binding 2b protein derived from Tomato aspermy virus was genetically modified by fusing the integrin-targeting RGD peptide to its C-terminus, and biosynthesized. The resulting 2b-RGD protein possesses distinct characteristics favorable for biomedical applications of siRNA: (i) high affinity for siRNA, (ii) siRNA protection against RNases in serum, (iii) low cytotoxicity compared to the polycationic polymers often employed in conventional siRNA carriers, (iv) specific binding to integrins on cancer cells, and the ability to pass through the cell membrane via endocytosis, and (v) the ability to facilitate cytosolic release of siRNA. Here, we demonstrate that the 2b-RGD/siRNA complexes have great potential as a tumor-targeting siRNA delivery carrier and suggest their possible therapeutic applications for cancer treatment. (C) 2014 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved. English ELSEVIER SCI LTD RNA-SILENCING SUPPRESSION CHIMERIC CAPSID PROTEIN ANTIVIRAL IMMUNITY BINDING DOMAIN GENE DELIVERY EFFICIENT INTERFERENCE INTEGRIN CELLS Genetically modified Tomato aspermy virus 2b protein as a tumor-targeting siRNA delivery carrier Article 10.1016/j.actbio.2014.07.014 1 ACTA BIOMATERIALIA, v.10, no.11, pp.4778 - 4786 ACTA BIOMATERIALIA 10 11 4778 4786 scie scopus 000343854400024 2-s2.0-84908143741 Engineering, Biomedical Materials Science, Biomaterials Engineering Materials Science Article RNA-SILENCING SUPPRESSION CHIMERIC CAPSID PROTEIN ANTIVIRAL IMMUNITY BINDING DOMAIN GENE DELIVERY EFFICIENT INTERFERENCE INTEGRIN CELLS RNAi siRNA delivery carrier Tumor-targeting Cancer treatment Recombinant proteins